Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — C21 BioVentures Conference 2011
17 slides from Aethlon Medical's conference presentation, May 31, 2011
Slide 1: C21 BioVentures Conference
aethlon MEDICAL, INC. C21 BioVentures Conference May 26, 2011 Jim Joyce Chairman, CEO
Slide 2: Forward Looking Statements
Slide 3: Pioneering the Selective Therapeutic Filtration Industry
Pioneering the Selective Therapeutic Filtration Industry
Slide 4: Our objective at C21 is to introduce our Aethlon ADAPT system
Our objective at C21 is to introduce our Aethlon ADAPT™ system
Slide 5: The Aethlon ADAPT™ System
The Aethlon ADAPT™ System Adaptive Dialysis-like Affinity Platform Technology + Converges proven plasma filter technology with antibodies or other affinity drug agents + An extracorporeal therapeutic with a much less aethion 7)
Slide 6: The Aethlon ADAPT™ System Repurposes
The Aethlon Adapt™ System Repurposes * Clinical Stage Agents + Approved Agents aethion DD
Slide 7: The Hemopurifier®
The Hemopurifier® The first medical device to selectively remove infectious viruses and immunosuppressive toxins from circulation
Slide 8: The Hemopurifier®: A Broad-Spectrum Therapeutic Device
The Hemopurifier® A Broad-Spectrum Therapeutic Device Hepatitis C HIV Bioterror & Pandemic Threats Cancer Secreted Exosomes
Slide 9: Aethlon ADAPT™ System Advantages
Aethlon ADAPT™ System Advantages + Allows immediate target clearance without adding drug toxicity or interaction risks to other therapies + Allows increased dosing of drug agents vs. systemic delivery + Allows immobilization of an individual or multiple drug agent cocktail within a single aethlon/@)
Slide 10: The Medical Device Pathway
The Medical Device Pathway An executable commercialization strategy + United States - FDA + Safety & Pivotal Study + European Union — CE Mark aethlon/@)
Slide 11: ADAPT devices delivered through global dialysis infrastructure
Aethion ADAPT™ system devices can be delivered through an established global infrastructure of dialysis stations (90,000+ in U.S.)
Slide 12: Additional Delivery Infrastructure
Additional Delivery Infrastructure * CRRT machines already located in hospitals and clinics ¢ Portable pump configurations
Slide 13: The Future
The Future Home Delivery of Therapeutic Devices Evolved From The Aethlon ADAPT™ System
Slide 14: Current Adapt™ System Pipeline
Current Adapt™ System Pipeline * The Hemopurifier® + Device to reduce incidence of sepsis + Proposed in DARPA DLT contract response * Device to treat sepsis aethion! a
Slide 15: The Aethlon ADAPT™ System
The Aethlon ADAPT™ System Adaptive Dialysis-like Affinity Platform Technology + Converges proven plasma filter technology with antibodies or other affinity drug agents - An extracorporeal therapeutic with a much less aethlon 7)
Slide 16: Presenter Information
Presenter Information Jim Joyce Chairman, CEO
Slide 17: 8910 University Center Lane, Suite
8910 University Center Lane, Suite 660